Sep 2026
Discovery of INCB127443: A Potent and Orally Available Inhibitor of Cyclin-Dependent Kinase 2
CDK2 is a critical regulator of cell-cycle progression and is an attractive therapeutic target for cancers characterized by dysregulated cyclin E1 signaling. Despite this biological rationale, CDK2 has historically been challenging to target due to the difficulty of achieving selectivity over related CDK isoforms, pa...
Ken Mukai, Brandon R. Smith, Qin-Da Ye et al.
· Journal of Medicinal Chemist... · 0 citations